



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

2390 5 JUL 15 A9:37

Food and Drug Administration  
Rockville MD 20857

Re: Clarinex  
Docket No.: 02E-0097

The Honorable Jon Dudas  
Under Secretary of Commerce for Intellectual Property and  
Director of the United States Patent and Trademark Office  
Box Pat. Ext.  
P.O. Box 1450  
Alexandria, VA 22313-1450

JUL - 8 2005

Dear Director Dudas:

This is in regard to the application for patent term extension for U.S. Patent No. 4,659,716, filed by Schering Corporation, under 35 U.S.C. section 156 et seq. We have reviewed the dates contained in the application and have determined the regulatory review period for Clarinex, the human drug product claimed by the patent.

The total length of the regulatory review period for Clarinex is 1,354 days. Of this time, 561 days occurred during the testing phase and 793 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under subsection 505(i) of the Federal Food, Drug, and Cosmetic Act involving this drug product became effective: April 9, 1998.

FDA has verified the applicant's claim that the date the investigational new drug application became effective was on April 9, 1998.

2. The date the application was initially submitted with respect to the human drug product under section 505(b) of the Federal Food, Drug, and Cosmetic Act: October 21, 1999.

FDA has verified the applicant's claim that the new drug application (NDA) for Clarinex (NDA 21-165) was initially submitted on October 21, 1999.

3. The date the application was approved: December 21, 2001.

FDA has verified the applicant's claim that NDA 21-165 was approved on December 21, 2001.


02E-0097

LET 3

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. section 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Jane A. Axelrad", written in a cursive style.

Jane A. Axelrad

Associate Director for Policy  
Center for Drug Evaluation and Research

cc: Thomas D. Hoffman  
Schering Plough Corporation  
Patent Department  
2000 Galloping Hill Rd.  
Kenilworth, NJ 07033-0530